trial

A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia

NCTId NCT07423546
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1, Phase 2 · Not Yet Recruiting
Enrollment 12 (estimated)
Sponsored by New York State Psychiatric Institute, Washington Heights Community Service
Primary completion 2027-04-30
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1, Phase 2
Status
Not Yet Recruiting
Enrollment
12 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2026-07-01
Primary completion
2027-04-30
Eligibility
ALL · 18 Years · 50 Years

Interventions & indications

Drugs
Xanomeline-trospium (Cobenfy)

Sponsors

New York State Psychiatric Institute, Washington Heights Community ServiceLead Sponsor
Bristol-MyersCollaborator

Investigators

2
Joshua T Kantrowitz, MDPrincipal Investigator
Ragy R Girgis, MDPrincipal Investigator

Sites

1 total
New York, United States

Linked catalysts

1
A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia — primary completion2027-04-30

Facts & assertions

4 sourced
Enrollment
12
Phase
PHASE1,PHASE2
Primary Completion Date
2027-04-30
Status
NOT_YET_RECRUITING
relationships
The graph out of here
drug
Xanomeline-trospium (Cobenfy)
drug
lead_sponsor
New York State Psychiatric Institute, Washington Heights Community Service
company
collaborator
Bristol-Myers
company
indication
Schizoaffecitve Disorder
indication
SCHIZOPHRENIA 1 (Disorder)
indication
investigator
Joshua T Kantrowitz, MD
person
Ragy R Girgis, MD
person